Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms
Launched by FRANCESCO DE COBELLI · Jun 7, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called microwave ablation (MWA) for patients with small kidney tumors and certain types of liver cancer. The main goal is to gather information about how effective and safe this treatment is for people who have primary liver cancer (the cancer started in the liver) or secondary liver cancer (the cancer spread to the liver from another part of the body, like colon cancer), as well as small kidney tumors. Researchers will follow the patients over time to see how they respond to the treatment.
To be eligible for this trial, participants must be adults over 18 years old with small tumors that cannot be treated with standard surgery. This includes having up to three liver nodules that are 3 cm or smaller or one or more kidney tumors that are less than 4 cm. Pregnant women or those with certain medical conditions will not be included in the study. Participants will continue with their usual medical care while the study collects data on their treatment outcomes, which means their normal healthcare routine will not change. This trial is currently recruiting participants of all genders, so if you or a loved one meet the criteria, it may be a good opportunity to explore a new treatment option.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \> 18 years with primary or secondary liver tumors or small kidney tumors that are not candidates for surgery or cannot be radically resected by surgery alone
- • Primary liver cancer: up to three liver nodules ≤ 3 cm
- • Secondary hepatic tumours: up to nodules ≤ 3 cm provided that the objective is complete hepatic clearance Renal tumours: single or multiple (von Hippel Lindau syndrome), \< 4 cm
- Exclusion Criteria:
- • pregnant women
- • non-manageable coagulopathies
- • Extended extrahepatic or extrarenal disease
- • for liver ablation: presence of bilio-digestive anastomosis
About Francesco De Cobelli
Francesco De Cobelli is a prominent clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic approaches, the organization specializes in conducting rigorous clinical trials across various therapeutic areas, ensuring adherence to the highest ethical and scientific standards. Led by a team of experienced researchers and healthcare professionals, Francesco De Cobelli is dedicated to fostering collaboration and transparency in the research process, ultimately contributing to the development of effective treatments and enhancing healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milano, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials